In March 2020, permission was given to trial HCQ for the treatment of covid to prevent hospitalization. We had a national stockpile of HCQ. The goal was to give HCQ to patients at the onset of the virus to slow it in its tracks and prevent serious illness. Alex Azar, Janet Woodcock, and Rick Bright all gave consent to trail HCQ on covid patients, but with a caveat. They could only trial it in a HOSPITAL, on patients already HOSPITALIZED with covid. Doesn’t that defeat the whole purpose of early treatment? Deploying HCQ at first signs of illness or covid positive test? Wait until they are so sick they require hospitalization? (Hint, this trial was designed to fail and run HCQ through the mud).
On April 2, 2020, Vanderbilt said that they enrolled the first patients in ORCHID. Vanderbilt University Medical Center: "The ORCHID trial ... funded by the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health, enrolled its first patient on April 2 and will include hundreds of patients to determine if hydroxychloroquine is an effective treatment against the virus projected to hospitalize thousands of U.S. residents in the coming weeks."
The screenshot below is from a press release that was included in email correspondence included in the FOIA request of Judicial Watch. I still have some questions about the funding and origins of the ORCHID trials, but they were clearly associated with the NIH at Vanderbilt.
On April 6, 2020, Katie Pavlich published "Thousands of Doctors: Yes, Hydroxychloroquine Works Against Wuhan Coronavirus" on Townhall. "Dr. Anthony Cardillo said he has seen very promising results when prescribing hydroxychloroquine in combination with zinc for the most severely-ill COVID-19 patients. ... Dr. Mohammud Alam, an infectious disease specialist affiliated with Plainview Hospital, said 81 percent of infected covid patients he treated at three Long Island nursing homes recovered from the contagion.
On April 24, 2020, FDA issued a Drug Safety Communication (DSC) cautioning against the use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of arrhythmias. The DSC described reports of serious cardiac events, including QT prolongation, in patients receiving hydroxychloroquine or chloroquine, often in combination with azithromycin and other QT prolonging medicines, for the prevention or treatment of COVID-19. FDA Review HCL & Chloroquine. The FDA is cautioning against the same thing the NIH is testing, azithromycin, at this point.
On April 29, 2020, Anthony Fauci praised very weak results of a Remdesivir study. Anthony Fauci: "The data shows that Remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery. ... If you look at the time to recovery being shorter in the Remdesivir arm, it was 11 days compared to 15 days. On April 29, 2020, Ralph Baric said that the results of the Remdesivir clinical trial was a "game changer."
Note that UNC claimed they developed Remdesivir at the University of North Carolina. "Remdesivir was developed through an academic-corporate partnership between Gilead Sciences and the Baric Lab at the University of North Carolina at Chapel Hill’s Gillings School of Global Public Health." That's extremely misleading, and distracts from Vanderbilt's role in developing Remdesivir. This UNC press release distracts from Vanderbilt's financial and academic conflict of interest in testing HCL in their ORCHID trials.
So to recap here. Vanderbilt is financially in bed with Fauci and Baric to make sure Remdesivir is the DRUG OF CHOICE. So what better place to trial HCQ and make sure it fails than……Vanderbilt.
No comments:
Post a Comment